JNJ-55308942 is an investigational drug that works as a P2X7 antagonist with a downstream effect of reducing interleukin-1β release. It is developed by Janssen…
JNJ-55308942 is an investigational drug that works as a P2X7 antagonist with a downstream effect of reducing interleukin-1β release. It is developed by Janssen Pharmaceuticals for bipolar depression.
See also List of investigational bipolar disorder drugs JNJ-54175446
References
Gebaseerd op: Wikipedia — JNJ-55308942 · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.